http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-325008-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
filingDate 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d19bbca22f41ebcde62451b2573d8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6421bffda7ffbc13e5b8958d0aa2586e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c563ae7386f419bd6ede49d92d21ef4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cd896d02f0a225e704543422bea06d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4614955bb8a480b463637fda3a96d66b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cabc765bf3c49b959b63d0a7d996af7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93635decfd4e628ef854d34a0c08a8a9
publicationDate 2008-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NO-325008-B1
titleOfInvention Adenosine A2A Receptor Antagonists
abstract There are disclosed compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl. cycloalkenyl or heteroaryl, X is alkylene or -. C (O) CH-, Y is -N (R) CHCHN (R) -, - OCHCHN (R) -, -O-, -S-, -CHS-, - (CH) -NH-, or optionally substituted , (Ia) ,. m and n are 2-3, and Q is nitrogen or optionally substituted carbon, and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, RC (O) -, RSO-, ROC (0) -, R C (O) -, RN (R) -C (S) -, phenyl-CH (OH) - or phenyl-C (= NOR) -, or if Q is CH, (Ib),
priorityDate 2000-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030

Total number of triples: 37.